FORM PTO-1390 (REV 11-2000)	U.S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 117-363
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO (If known, see 37 C.F.R. 1.5) 09/Unknown 914184
INTERNATIONAL APPLICATION NO. **PCT/US00/04699**	INTERNATIONAL FILING DATE **25 February 2000**	PRIORITY DATE CLAIMED **26 February 1999**

TITLE OF INVENTION

SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES

APPLICANT(S) FOR DO/EO/US

TAN et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The U.S. has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
   - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   - b. ☒ has been communicated by the International Bureau.
   - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   - a. ☐ is attached hereto.
   - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   - b. ☐ have been communicated by the International Bureau.
   - c. ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
   - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 To 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information. PTO-1449/ International Search Report

JC12 Rec'd PCT/PTO 23 AUG 2001

U.S. APPLICATION NO (If known, see 37 C.F.R. 5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
09/914184 Unknown	PCT/US00/04699	117-363

21. ☒ The following fees are submitted:

	CALCULATIONS	PTO USE ONLY

BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):

-- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....$1000.00

-- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....$860.00

-- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO.....$710.00

-- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....$690.00

-- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =						$	860.00	
Surcharge of $130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).						$	130.00	
CLAIMS	NUMBER FILED		NUMBER EXTRA	RATE				
Total Claims	18	-20 =	0	X	$18.00	$	0.00	
Independent Claims	4	-3 =	1	X	$80.00		80.00	
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)					$270.00	$	0.00	
TOTAL OF ABOVE CALCULATIONS =						$	**1070.00**	
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.							0.00	
SUBTOTAL =						$	**1070.00**	
Processing fee of $130.00, for furnishing the English Translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)). +							0.00	
TOTAL NATIONAL FEE =						$	**1070.00**	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). **$40.00** per property +						$	0.00	
Fee for Petition to Revive Unintentionally Abandoned Application ($1240.00 – Small Entity = $620.00)						$	0.00	
TOTAL FEES ENCLOSED =						$	**1070.00**	
						Amount to be: refunded	$	
						Charged	$	

a. ☒ A check in the amount of $1070.00 to cover the above fees is enclosed.
b. ☐ Please charge my Deposit Account No. 14-1140 in the amount of $_____ to cover the above fees.
A duplicate copy of this form is enclosed.
c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.
d. ☒ The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.

NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

NIXON & VANDERHYE P.C.
1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000

Mary J. Wilson
SIGNATURE

Mary J. Wilson
NAME

32,955 **August 23, 2001**
REGISTRATION NUMBER Date

553988

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

TAN et al. Atty. Ref.: 117-363

Serial No. Unknown Group:

Filed: August 23, 2001 Examiner:

For: SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES

* * * * * * * * * * * *

August 23, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for examination, please amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-21 without prejudice or disclaimer.

Please add new claims 22-39 as follows.

22. A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises administering to the host effective amounts of:

(a) an interferon, and

(b) at least one compound selected from the group consisting of:

- 5-membered cyclic nucleosides having the formula (I):



(I)

wherein "X" is =CH-, $-CH_2-$ or -O-, Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, C-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;

- mycophenolic acid compounds having the formula (II)



(II).

wherein R_4 is $-OR_6$ or $-N(R_7)\ R_8$ in which R_6, R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1-C_6 alkyl, and R_5 is selected from the group consisting of hydrogen, phenyl and C_1-C_6 alkyl

unsubstituted or substituted by a five- or six-membered saturated or unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;

- imidazole derivatives represented by formula (III):



(III).

wherein R_9 is a hydrogen atom or



wherein R_{10} is a hydrogen atom, C_1-C_6 alkyl, hydroxy(C_1-C_6 alkyl) or phenyl, R_{11} and R_{13} are independently selected from hydrogen and OR_{12} and R_{12} is a hydrogen atom or a hydroxy protecting group and A is $CONH_2$ or CN, and pharmaceutically acceptable salts thereof;

- aminoadamantanes having the formula (IV):



(IV).

wherein each of R_{14}, R_{15}, R_{16} and R_{17} is independently selected from the group consisting of H, F and CH_3 and X is $N(R_{18})_2$, $CH_2CH_2N(R_{18})_2$ or $C(R_{19})_2N(R_{18})_2$ wherein each R_{18} and R_{19} is H, (C_1-C_6) alkyl, (C_6-C_{10}) aryl and (C_7-C_{18}) aralkyl; and

2,4-diaminopyrimidines having the formula (V):



(V)

wherein R_{20}

is phenyl substituted by one or more substituents selected from the group consisting of benzyl, NO_2, (C_1-C_6) alkylamino and halogen and R_{21} is H or C_1-C_6 alkyl; or R_{20} and R_{21} form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):



(V')

wherein Z is $-CH_2NR_{23}-$ or $-NR_{23}CH_2-$; R_{22}, R_{23} and R_{24} are each, independently, H or C_1-C_6 alkyl; and n is 1 or 2,and pharmaceutically acceptable salts thereof.

23. A method according to claim 22, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

24. A method according to claim 22, wherein the rhabdovirus is selected from vesicular stomatitis virus (VSV) and rabies virus.

25. A method according to claim 22, wherein the interferon (a) is a human interferon.

26. A method according to claim 22, wherein the interferon is selected from interferon α2, interferon α8 and interferon β.

27. A method according to claim 26, wherein the interferon is human interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg protein.

28. A method according to claim 26, wherein the interferon is human interferon β having a specific activity of from $4x10^8$ to $8x10^8$ per mg protein.

29. A method according to claim 22, wherein the compound (b) is at least one compound selected from cyclopentenyl cytosine, mycophenolic acid, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide, amantadine hydrochloride, 3-deazaneplanocin, neplanocin A, 3-deazauridine, 6-azauridine, aristeromycin, pyrazofurin, tiazafurin, selenofurin, NSC 382046, NSC 7364, NSC 302325, NSC 184692D and NSC 382034.

30. Products containing an interferon and at least one compound (b) as defined in claim 22 as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection.

31. A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises administering an effective amount of an interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg protein.

32. A method according to claim 31, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

33. A method according to claim 31, wherein the rhabdovirus is VSV.

34. A method according to claim 31, wherein the interferon α8 is human interferon α8.

35. Interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg of protein for use in a method of treatment of the human or animal body by therapy.

36. Interferon α8 according to claim 35, for use in the treatment of a flavivirus or rhabdovirus infection.

37. An anti-flavivirus or anti-rhabdovirus agent comprising interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg of protein.

38. A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic antiflaviviral or antirhabdoviral effect, an interferon and at least one compound (b) as defined in claim 22.

39. An agent for use in the treatment of a flavivirus or rhabdovirus infection, which comprises an interferon and at least one compound (b) as defined in claim 22.

REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Mary J. Wilson

Mary J. Wilson
Reg. No. 32,955

MJW:ms
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES

Field of the Invention

This invention relates to the use of interferons as antiviral agents.

Background to the Invention

Human interferons (IFN) were originally prepared from human white blood cells, a by-product of blood banks, and from primary human fibroblasts in culture. The white cell product was called human leukocyte interferon or human alpha interferon and the human fibroblast interferon was called human β interferon. Subsequent to the cloning of interferons in *E. coli*, several subtypes of human interferons have been identified. There are at least 15 subtypes of alpha interferon (Henco K. *et al.*, J. Mol Biol. 185, 227-260, 1985) and only one β interferon.

Cyclopentenyl cytosine (CPE-C) was a promising anti-tumor compound in clinical trial until two deaths were observed in the trial. Four of the eleven patients who received 4.7 mg/m^2 per hour of CPE-C experienced hypotension 24 to 48 hours after completion of the CPE-C infusion during their first, third and sixth cycles respectively. Two of the four hypotensive patients died with refractory hypotension. The trial was immediately stopped by the National Cancer Institute, USA. Hypotension was not seen in patients receiving $\leq$2.5 mg/m^2 per h CPE-C (Cancer Chemother. Pharmacol. 36, 513-523, 1995). The mean CPE-C steady-state plasma levels (Cpss) increased linearly from 0.4μM to 3.1μM at doses ranging from 1 to 5.9 mg/m^2/h.

Mycophenolic acid was first demonstrated by H. Florey in 1946 to inhibit bacteria, fungi and leukocytes. The prodrug mycophenolate mofetil is now an FDA-approved transplantation drug.

Summary of the Invention

We have now found that an interferon such as interferon α2, interferon α8 or interferon β can act synergistically with particular compounds to combat flavivirus

and rhabdovirus infections. This synergistic antiviral effect means that lower concentrations of the small molecular weight chemicals such as CPE-C can be used together with interferons as antiflaviviral and antirhabdoviral agents and at concentrations below its anticipated side effects (hypotension) in man (1.0 μM or less).

Accordingly, the present invention provides a method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host in respective amounts which produce a synergistic antiflaviviral or synergistic antirhabdoviral effect:

(a) an interferon, and

(b) at least one compound selected from the group consisting of:

- 5-membered cyclic nucleosides having the formula (I):



(I)

wherein ⌢X⌢ is =CH-, $-CH_2-$ or -O-, Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;

- mycophenolic acid compounds having the formula (II)



(II).

wherein R_4 is $-OR_6$ or $-N(R_7)\ R_8$ in which R_6, R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1-C_6 alkyl, and R_5 is selected from the group consisting of hydrogen, phenyl and C_1-C_6 alkyl unsubstituted or substituted by a five- or six-membered saturated or unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;

- imidazole derivatives represented by formula (III):



(III).

wherein R_9 is a hydrogen atom or



wherein R_{10} is a hydrogen atom, C_1-C_6 alkyl, hydroxy(C_1-C_6 alkyl) or phenyl, R_{11} and R_{13} are independently selected from hydrogen and OR_{12} , R_{12} is a hydrogen atom or a hydroxy protecting group and A is $CONH_2$ or CN, and pharmaceutically acceptable salts thereof;

- aminoadamantanes having the formula (IV):



(IV).

wherein each of R_{14}, R_{15}, R_{16} and R_{17} is independently selected from the group consisting of H, F and CH_3 and X is $N(R_{18})_2$, $CH_2CH_2N(R_{18})_2$ or $C(R_{19})_2N(R_{18})_2$ wherein each R_{18} and R_{19} is H, (C_1-C_6) alkyl, (C_6-C_{10}) aryl and

(C_7-C_{18}) aralkyl; and

- 2,4-diaminopyrimidines having the formula (V):



(V)

wherein R_{20} is phenyl substituted by one or more substituents selected from the group consisting of aralkyl, NO_2, (C_1-C_6) alkylamino and halogen and R_{21} is H or C_1-C_6 alkyl; or R_{20} and R_{21} form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):



(V')

wherein Z is $-CH_2NR_{23}-$ or $-NR_{23}CH_2-$; R_{22}, R_{23} and R_{24} are each, independently, H or C_1-C_6 alkyl; and n is 1 or 2, and pharmaceutically acceptable salts thereof.

In formula (V) the aralkyl substituent is an aryl group linked via an alkylene chain of 1 to 6 carbon atoms. Aryl is typically phenyl or naphthyl. Preferred examples of aralkyl are benzyl and phenethyl. In formula (V') R_{22} is preferably methyl or ethyl, especially ethyl, R_{23} and R_{24} are preferably H and n is preferably 1.

The present invention encompasses all optical isomers of the compound (b), in particular the D- and L-isomers of the nucleosides of formula (I) and of the quinazoline derivatives of formula (V').

rhabdovirus infections also forms part of the invention. The invention therefore further provides a method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host a therapeutically effective amount of an interferon α8 having a specific activity of from $0.3x10^9$ to $3x10^9$ IU per mg protein.

The invention additionally provides:

- use of an interferon in the manufacture of a medicament for use with at least one compound (b) as defined above in the treatment of a flavivirus or rhabdovirus infection;
- use of at least one compound (b) as defined above in the manufacture of a medicament for use with an interferon in the treatment of a flavivirus or rhabdovirus infection;
- products containing an interferon and at least one compound (b) as defined above as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection;
- interferon α8 having a specific activity of from $0.3x10^9$ to $3x10^9$ IU per mg of protein for use in a method of treatment of the human or animal body by therapy;
- use of interferon α8 having a specific activity of from $0.3x10^9$ to $3x10^9$ IU per mg of protein in the manufacture of a medicament for use in the treatment of a flavivirus or rhabdovirus infection; and
- an anti-flavivirus or anti-rhabdovirus agent comprising interferon α8 having a specific activity of from $0.3x10^9$ to $3x10^9$ IU per mg of protein.

Detailed Description of the Invention

Interferons

The interferon for use in the present invention may be an interferon α, such as interferon α2 or α8, or interferon β. The term "interferon" includes fragments which have interferon activity and mutant forms of an interferon which retain interferon activity. For example, the sequence of an interferon α or β may have been modified to enhance activity or stability as reported in US-A-5582824, US-A-5593667 or US-

A-5594107.

The interferon may have been purified from natural sources or may be a recombinant interferon. The species of interferon is generally the same as the host species to which the interferon is administered. The invention is particularly applicable to the treatment of flavivirus infections in humans. Preferably therefore a human interferon such as human interferon α2 or α8 or human interferon β is used.

The interferon α8, particularly the human interferon α8, typically has a specific activity of more than $0.6x10^9$, generally from $0.6x10^9$ to $1.5x10^9$ and preferably from $0.8x10^9$ to $1.5x10^9$, IU per mg protein. The human interferon β typically has a specific activity of from $4x10^8$ to $8x10^8$, preferably from $4.8x10^8$ to $6.4x10^8$, IU per mg protein. Interferon α and interferon β specific activities are determined according to reference standards Gb-23-902-530 and Gb-23-902-531 respectively. Specific activity is determined according to a modification of the method of Armstrong, Applied Microbiology 21, 723, 1971, in which 0.2 μg/ml of actinomycin D is included in the viral challenge and the viral induced cytopathic effect (CPE) is read directly from the primary human fibroblasts. Alternatively, specific activity is determined according to the method of Armstrong using WISH cells as assay cells and Encephalomyocarditis virus as challenge virus and the viral induced CPE is read directly.

The interferon such as the interferon α2 or α8 or the interferon β is preferably obtainable by the methodology of WO 96/30531. The interferon is thus obtainable by a process comprising culturing mammalian cells transfected with a nucleic acid vector comprising:

(i) a coding sequence which encodes the interferon and which is operably linked to a promoter capable of directing expression of the coding sequence in mammalian cells in the presence of a heavy metal ion;

(ii) a first selectable marker sequence which comprises a metallothionein gene and which is operably linked to a promoter capable of directing expression of the metallothionein gene in the cells in the presence of a heavy metal ion; and

(iii) a second selectable marker sequence which comprises a *neo* gene and which is operably linked to a promoter capable of directing expression of the *neo*

gene in the cells;

unless conditions that allow expression of the coding sequence; and recovering the interferon thus produced.

The transfected mammalian cells may be cells of a human or animal cell line. They may be BHK, COS, CHO Lec2, L CL3, Vero, human fibroblastoid such as C1O, HeLa, or human lymphoblastoid cells or cells of a human tumour cell line. Preferably, however, the cells are CHO cells, particularly wild-type CHO cells.

Desirably, transfected cells will have all or part of such a vector integrated into their genomes. Such cells are preferred because they give stable expression of the coding sequence contained in the vector. Preferably, one or more copies of the entire vector will be integrated, with cells having multiple integrated copies of the vector, for example from 20 to 100 copies or more, being particularly preferred because these cells give a high stable level of expression of the coding sequence contained in the vector.

However, cells having less than complete sections of the vectors integrated into their genomes can be employed if they are functionally equivalent to cells having the entire vector integrated into their genomes, in the sense that the integrated sections of the vector enable the cell to express the coding sequence and to be selected for by the use of heavy metals. Thus, cells exhibiting partial integration of a vector may be employed if the integrated element or elements include the coding sequence operably linked to its associated promoter and the metallothionein marker sequence operably linked to its associated promoter.

Any promoter capable of enhancing expression in a mammalian cell in the presence of a heavy metal ion such as Cd^{2+}, Cu^{2+} and Zn^{2+} may be operably linked to the interferon coding sequence. A suitable promoter is a metallothionein gene promoter. The mouse metallothionein gene I (mMT1) promoter is preferred.

Suitable promoter/enhancer combinations for the coding sequence include the mMT1 promoter flanked upstream with a mouse sarcoma virus (MSV) enhancer (MSV-mMT1) and a Rous sarcoma virus (RSV) enhancer upstream of a mouse mammary tumour virus (MMTV) promoter. MSV-mMT1 is preferred.

As far as the first selectable marker sequence is concerned, any promoter

capable of enhancing expression in a mammalian cell in the presence of a heavy metal ion such as Cd^{2+}, Cu^{2+} and Zn^{2+} may be operably linked to the metallothionein gene such as a human metallothionein gene. Preferably, the marker sequence gene is a human metallothionein gene, such as the human metallothionein gene IIA, which has its own promoter.

The second selectable marker sequence is a *neo* gene. More than one type of this gene exists in nature: any specific *neo* gene can be used in a vector of the invention. One preferred *neo* gene is the *E.coli neo* gene.

The promoter for the *neo* gene is capable of directing expression of the gene in a mammalian cell. Suitable promoters are the cytomegalovirus (CMV) early promoter, the SV40 promoter, the mouse mammary tumour virus promoter, the human elongation factor 1 α-P promoter (EF-1α-P), the SRα promoter and a metallothionein gene promoter such as mMT1. The promoter may also be capable of expressing the *neo* gene in bacteria such as *E.coli* in which a vector may be constructed.

The interferon coding sequence (i) and the marker sequences (ii) and (iii) are thus each operably linked to a promoter capable of directing expression of the relevant sequence. The term "operably linked" refers to a juxtaposition wherein the promoter and the coding/marker sequence are in a relationship permitting the coding/marker sequence to be expressed under the control of the promoter. Thus, there may be elements such as 5' non-coding sequence between the promoter and coding/marker sequence. Such sequences can be included in the construct if they enhance or do not impair the correct control of the coding/marker sequence by the promoter.

The vector may be a DNA or RNA vector, preferably a DNA vector. Typically, the vector is a plasmid. Each of the sequences (i) to (iii) will typically be associated with other elements that control their expression. In relation to each sequence, the following elements are generally present, usually in a 5' to 3' arrangement: a promoter for directing expression of the sequence and optionally a regulator of the promoter, a translational start codon, the coding/marker sequence, a polyadenylation signal and a transcriptional terminator.

Further, the vector typically comprises one or more origins of replication, for example a bacterial origin of replication, such as the pBR322 origin, that allows replication in bacterial cells. Alternatively or additionally, one or more eukaryotic origins of replication may be included in the vector so that replication is possible in, for example yeast cells and/or mammalian cells.

The vector may also comprise one or more introns or other non-coding sequences 3' or 5' to the coding sequence or to one or more of the marker sequences. Such non-coding sequences may be derived from any organism, or may be synthetic in nature. Thus, they may have any sequence. Such sequences may be included if they enhance or do not impair correct expression of the coding sequence or marker sequences.

The transfected cells are typically cultured in the presence of a heavy metal ion selected from Cd^{2+}, Cu^{2+} and Zn^{2+}, particularly in an amount which is not toxic to the cells. That can lead to higher expression of the desired interferon. The concentration of the heavy metal ion in the culture medium is typically from 100 to 200 μM. Cells may therefore be cultured in the presence of from 100 to 200 μM of a heavy metal ion selected from Cd^{2+}, Cu^{2+} and Zn^{2+}, for example from 130 to 170 μM of the heavy metal ion. A useful concentration is about 150 μM, particularly when the heavy metal ion is Zn^{2+}.

The interferon that is produced may be recovered by any suitable means and the method of recovery may vary depending on, for example, the type of cells employed and the culture conditions that have been used. Desirably, the interferon produced will be purified after recovery. Substantially pure interferon can thus be obtained.

The human β-interferon provided by WO 96/30531 has a high degree of sialylation. Like natural human β-interferon produced by primary diploid human fibroblasts, it is well glycosylated. However, it has a higher bioavailability than the natural β-interferon or recombinant β-interferon produced in *E.coli* (betaseron).

The higher bioavailability of the β-interferon can be characterised. When 1.5 x 10^6 IU of the interferon is injected subcutaneously into the back of a rabbit of about 2 kg: (a) ≥ 128 IU/ml of the interferon is detectable in the serum of the rabbit after 1

hour, and/or (b) ≥ 64 IU/ml of the interferon is detectable in the serum of the rabbit after 5 hours.

The maximum level of interferon is typically observed after 1 hour. According to (a), therefore, 128 to 256 IU/ml such as 140 to 190 IU/ml of the interferon may be detectable in the rabbit serum after 1 hour. After 5 hours according to (b), ≥ 70 IU/ml such as ≥ 80 IU/ml of the interferon may be detectable in the rabbit serum. Typically according to (b), an amount of interferon in the range of 64 to 128 IU/ml such as 80 to 110 IU/ml can be detected.

Additionally or alternatively, the human interferon β can be characterised by its specific activity. It can have a specific activity from 4.8×10^8 to 6.4×10^8 IU per mg equivalent of bovine serum albumin protein, as noted above. The specific activity may be from 5×10^8 to 6×10^8, for example from 5.2×10^8 to 5.8×10^8 such as from 5.3×10^8 to 5.5×10^8, IU per mg equivalent of bovine serum albumin protein.

The human interferon β may also be characterised by one or more of the following properties:

1. The interferon β typically has an apparent molecular weight of 26,300 as determined by 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
2. When injected as a neat intravenous bolus into a rabbit, the half life of the interferon is typically in the range of from 12 to 15 min such as about 13½ min. The bolus is injected into the rabbit ear vein and blood samples are withdrawn from the rabbit ear artery. Rabbit serum is assayed for the antiviral activity of the interferon according to the modification of the method of Armstrong (1971).
3. The antiviral activity of the interferon in a human hepatoblastoma cell line (HepG2) is at least equal to and, typically, about 1.5 times the activity of natural interferon β from primary diploid human fibroblast cells. The interferon is also about 2.2 times more effective than betaseron in protecting Hep2 cells against a viral challenge. Antiviral activity is again determined according to the modified method of Armstrong (1971). Actinomycin D was

omitted in the antiviral determination in HepG2 cells.

The oligosaccharides associated with the interferon β of the invention may also characterise the interferon β. The interferon β carries oligosaccharides which can be characterised by one or more of the following features:

1. Neutral (no acidic substituents): 5 to 15%, preferably about 10% or lower. Acidic : 95 to 85%, preferably about 90% or higher.
2. The total desialylated oligosaccharide pool is heterogeneous with at least six distinct structural components present in the pool.
3. Matrix-Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF) mass spectrometry and high resolution gel permeation chromatography data are summarised as follows:

Mass detected	Composition	Calculated Mass	gu equivalent
1786.2	5Hex, 4HexNAc, 1 2AB, Na	1782	11.1
1929.9	5Hex,1dHex, 4HexNAc, 1 2AB, Na	1928	12.2
2295.5	6Hex, 1dHex, 5HexNAc 1 2AB, Na	2293	14.5
2660.1	7Hex, 1dHex, 6HexNAc 1 2AB, Na	2658	17.6
3019.1	8Hex, 1dHex, 7HexNAc, 1 2AB, Na	3023	20.7

The carbohydrate moiety of the human interferon β of WO 96/30531 consists of bi-, tri- and tetra-antennary complex type N-linked oligosaccharides. These oligosaccharides contain repeating lactosamine(s). About 20 to 50%, for example 20 to 30%, 30 to 40% or 35 to 50%, of the oligosaccharides are bi-antennary

oligosaccharides. About 30 to 65%, for example from 40 to 60% or 50 to 60%, of the oligosaccharides are tri-antennary oligosaccharides. About 2 to 15%, for example from 2 to 8%, 4 to 10% or 5 to 15%, of the oligosaccharides are tetra-antennary oligosaccharides. Percentages are calculated by weight of total analysable oligosaccharide content.

Compounds (b)

The compounds (b) are capable of inhibiting particular enzymes. Amongst the 5-membered cyclic nucleosides of formula (I), some of those in which ⌒X⌒ is -O-, such as pyrazofurin and 6-azauridine, are inhibitors of orotidylate decarboxylase whilst tiazofurin and selenofurin are inhibitors of inositol monophosphate dehydrogenase (IMPH). Compounds of formula (I) in which ⌒X⌒ is =CH- are typically inhibitors of cytosine triphosphate (CTP) synthetase and S-adenosylhomocysteine hydrolase.

The mycophenolic acid compounds of formula (II) and the imidazole derivatives of formula (III) are typically inhibitors of inosine monophosphate (IMP) dehydrogenase. The aminoadamantanes of formula (IV) inhibit the uncoating of influenza viruses. The 2,4-diaminopyrimidines of formula (V) and the quinazoline derivatives of formula (V') are inhibitors of dihydrofolate reductase.

In one embodiment the 5-membered cyclic nucleosides of formula (I) are cyclopentenyl carbocyclic nucleosides in which ⌒X⌒ is =CH-. These have the following structure (I'):



(I').

wherein R_1, R_2, R_3 and Nu are as defined above for formula (I).

Preferred 5-membered cyclic nucleosides of formula (I) and cyclopentenyl carbocyclic nucleosides of formula (I') are compounds in which Nu denotes one of

the following groups (i) to (viii):


(i)


(ii)


(iii)


(iv)


(v)


(vi)


(vii)


(viii)

wherein R_{25} is Cl or NH_2 and R_{26} is H, CH_3, CF_3, F, Cl, Br or I.

When one or more of R_1, R_2 and R_3 is O-acyl in formula (I) or (I'), the acyl group is preferably a group having the formula R_{27}-CO- in which R_{27} is C_1-C_6 alkyl such as C_1-C_4 alkyl, for example methyl or ethyl. The O-aryl group is generally a O-(C_6-C_{10}) aryl group such as O-phenyl or O-benzyl. R_2 and R_3 may together denote a ketal group such as



The 5-membered cyclic nucleosides of formula (I) are known compounds and

may be synthesised by published procedures or by analogy with published procedures. For instance the synthesis of carbocyclic adenosine [(±)-aristeromycin] is described by Shealy *et al* in J. Am Chem. Soc. 1966, 88, 3885 and in J. Am. Chem. Soc. 1969, 91, 3075. The enantioselective synthesis of (-) aristeromycin and (-)-neplanocin A is described by Arita *et al* in J.Am. Chem. Soc. (1983), 105 (12), 4049-4055.

The synthesis of pyrazofurin is described by Petrie *et al* in J. Med. Chem 1986, 29, 268-278. The synthesis of 6-azauridine is described by Cristescu in Rev. Roum. Chim (1968), 13(3), 365-9. The synthesis of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide) and selenofurin (2-β-D-ribofuranosylselenazole-4-carboxamide) is described by Hennen *et al* in J. Org. Chem (1985) 5O(10), 1741-1746. The synthesis of suitable cyclopentenyl carbocyclic nucleosides of formula (I') is described in US-A-4975434, the contents of which are incorporated herein by reference. Specific nucleosides are listed in that patent.

The substitution patterns of preferred compounds of formula (I) are shown in Table 1 below. A particularly preferred compound is cyclopentenyl cytosine (CPE-C).

Table 1: Substitution patterns within formula (I)

⌢ X ⌢	R_1	R_2	R_3	formula of Nu	Compound
=CH -	OH	OH	OH	(ii) wherein R_{25} is NH_2	3-deazaneplanocin
=CH-	OH	OH	OH	(i) wherein R_{25} is NH_2	neplanocin A
-O-	OH	OH	OH	(vi)	3-deazauridine
-O-	OH	OH	OH	(iv)	6-azauridine (NSC 32074)

$-CH_2-$	OH	OH	OH	(i) wherein R_{25} is NH_2	aristeromycin (NSC 103526)
-O-	OH	OH	OH	(v)	pyrazofurin (NSC 143095)
=CH-	OH	OH	OH	(iii) wherein R_{26} is H	cyclopentenylcytosine (CPE-C)
-O-	OH	OH	OH	(vii)	tiazofurin (NSC 286193)
-O-	OH	OH	OH	(viii)	selenofurin (NSC 340847)

As used herein the term "metabolite" refers to a compound for which a compound of formula (I) is a prodrug. For instance, tiazofurin and selenofurin are prodrugs for thiazolamide adenine dinucleotide (TAD) and selenazolamide adenine dinucleotide (SAD), respectively. In each case the metabolite, rather than the prodrug, is the active moiety. Examples of derivatives (or analogues) of these particular metabolites, which are also encompassed within the present invention, include beta-methylene TAD and beta-methylene SAD. These compounds are published in the literature.

The mycophenolic acid compounds of formula (II) include compounds in which R_4 is hydroxy or NH_2. When one or more of R_5, R_6, R_7 and R_8 is a C_1-C_6 alkyl group, preferably it is a C_1-C_4 alkyl group such as methyl or ethyl. The five- or six-membered saturated or unsaturated heterocyclic ring generally contains one, two or three N-atoms and optionally an O- and/or S-atom. Suitable such rings include pyridino, piperidino, pyrrolo, pyrrolidono and morpholino rings. A N-morpholino ring may thus be present.

Mycophenolic acid compounds for use in the invention include mycophenolic acid, mycophenolate mofetil which is the morpholinoethyl ester of mycophenolic acid, and the individual mycophenolic acid derivatives described in US-A-5380879. The contents of US-A-5380879 are incorporated herein by reference.

Suitable imidazole derivatives of formula (III) are compounds wherein R_{10} is hydrogen, C_1-C_4 alkyl such as methyl or ethyl, hydroxy(C_1-C_4 alkyl) in which the alkyl group may be methyl or ethyl, or phenyl. R_{12} may be hydrogen or any appropriate protecting group such as an acyl, alkyloxymethyl, substituted ethyl, aralkyl, pyranyl, silyl, acetal or ketal group. Typically, R_{11} and/or R_{13} is H or OH.

Imidazole derivatives of formula (III) are described in US-A-5126361, the contents of which are incorporated herein by reference. A particularly preferred imidazole derivative is 5-ethynyl-1-β-D-ribofuranosyl-imidazole-4-carboxamide (EICAR). EICAR is a compound of formula (III) in which A is $CONH_2$, R_9 is D-ribose and R_{10} is hydrogen.

Aminoadamantanes of formula (IV) are described in US-A-5599998, the contents of which are incorporated herein by reference. In formula (IV), R_{18} and R_{19} may each independently denote hydrogen, C_1-C_4 alkyl such as methyl or ethyl, phenyl or benzyl. Suitable compounds include 1-aminoadamantane ("amantidine"), α-methyl-1-adamantylmethylamine ("rimantadine") and 1-amino-3,5-dimethyladamantane ("momantine").

The synthesis of 2,4-diaminopyrimidines of formula (V) is described by D. J. Brown in the chapter "Pyrimidines and their Benzo Derivatives" in Comprehensive Heterocyclic Chemistry, Vol. 3, part 2B, A. Boulton and A. McKillop (Eds), 1983, Pergamon, Oxford, page 151, the contents of which are incorporated herein by reference. The substitution patterns of preferred compounds of formula (V) are shown in Table 2 below:

Table 2 Substitution patterns within formula (V)

R_{20}	R_{21}	Compound
	$-CH_2CH_3$	NSC 382046
	$-CH_3$	NSC 7364

	$-CH_2CH_3$	NSC 302325
	$-CH_2CH_3$	NSC 382034

The quinazoline derivatives of formula (V') may be synthesised as described by Hynes *et al* in J.Med. Chem., 1977, Vol 20, No. 4, 588-591 or by analogy with the methods described there. A preferred quinazoline derivative of formula (V') is the compound wherein R_{22} is C_2H_5, R_{23} and R_{24} are both H and n is 1. This is known as NSC 184692.

Pharmaceutically acceptable salts, particularly pharmaceutically acceptable acid addition salts, of any of the compounds of formula (I) to (IV) may be used. Salts with physiologically acceptable inorganic or organic acids may be employed, for example the hydrochloride salt.

Therapeutic uses

The interferons and compounds (b) are used together to treat flavivirus and rhabdovirus infections, particularly in humans. The infection may be acute or chronic. The flavivirus may be yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, or an encephalitis virus such as St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne

encephalitis virus. The rhabdovirus may be vesicular stomatitis virus (VSV) or rabies virus.

The interferon and at least one compound (b) are administered to a subject to be treated in sufficient amounts to produce a synergistic antiflaviviral or synergistic antirhabdoviral effect. The condition of the subject can thus be improved. The infection may be cleared from the subject entirely. Relative to monotherapy, lower doses of the interferon and of the compound(s) (b) can be used, which results in a cost-saving and a reduction or elimination of side effects that might occur at higher doses.

Separate formulations of the interferon on the one hand and of the compound(s) (b) on the other hand will generally be given to a patient. A single formulation containing both components can be administered if the interferon and compound(s) (b) are stable in each other's presence and do not otherwise interfere with each other.

The interferon may be administered to humans in various manners such as orally, intravenously, intramuscularly, intraperitoneally, intranasally, intradermally, topically and subcutaneously. The particular mode of administration and dosage regimen will be selected by the attending physician taking into account a number of factors including the age, weight and condition of the patient, the nature of the viral infection, the compound(s) (b) with which it is being administered and the need to obtain a synergistic effect.

The pharmaceutical compositions that contain the interferon as an active principal will normally be formulated with an appropriate pharmaceutically acceptable carrier or diluent depending upon the particular mode of administration being used. For instance, parenteral formulations are usually injectable fluids that use pharmaceutically and physiologically acceptable fluids such as physiological saline, balanced salt solutions, or the like as a vehicle. Oral formulations, on the other hand, may be solids, e.g. tablets or capsules, or liquid solutions or suspensions.

The interferon will usually be formulated as a unit dosage form that contains from 10^4 to 10^9, more usually 10^6 to 10^7, IU per dose. Typically from 3×10^6 to 18×10^6 IU of interferon is administered per day, particularly by injection such as

intravenously or subcutaneously. The dosage may be administered daily, for example for up to five or up to twenty weeks.

The compound(s) (b) can similarly be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions, topically such as in the form of creams, ointments or gels, or parenterally, for example intramuscularly, intravenously or subcutaneously. They may therefore be given by injection or infusion.

The mode of administration and dosage regimen of the compound(s) (b) also depends on a variety of factors including the particular compound(s) (b) concerned, the age, weight and condition of the patient, the nature of the viral infection and the need to obtain a synergistic effect. Typically, however, the dosage adopted for each route of administration for humans, for example adult humans, is 0.001 to 10 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, daily. The dosage may be given orally or by bolus infusion, infusion over several hours and/or repeated administration.

The interferon and the compound(s) (b) may be given simultaneously. Alternatively they may be given up to five days from each other, for example up to two days apart or up to one day apart or up to four hours apart. The relative timing of the administration of the interferon and the compound(s) (b) may be determined by monitoring their respective serum levels. The interferon may be given before the compound(s) (b) or *vice versa*. Two or three compound(s) (b) may be given, for example simultaneously or spaced apart timewise as above.

A suitable treatment regiment may be illustrated with reference to CPE-C. As noted previously, two patients treated with CPE-C died in a clinical trial as a result of hypotension. At dosages ≤ 2.5 mg/m^2/h no hypotension was observed. Consequently, interferon α8 or interferon β must be used with CPE-C at dosages of CPE-C below which substantial hyoptension occurs.

This may be achieved according to the invention by subcutaneous or intravenous injection of from 0.01 to 2.5 mg of CPE-C/m^2/h and from 3 to 18, for example 3, 6, 12 or 18, x 10^6 IU of interferon on day 1 The CPE-C may be injected simultaneously with the interferon. Alternatively, the interferon may be injected up

to 4 hours later, for example from 1 to 4 hours later. On days 2 and 3, 3 to $18x10^6$ IU of the interferon may be given to the patient. On day 4, the combination treatment of CPE-C and interferon can be repeated. This regimen may be repeated for several weeks, for example up to five or up to twenty weeks.

The following Examples illustrate the invention.

Example 1

Vero cells were grown to about 99% confluency in 96 microwells with minimum essential medium (MEM) containing 10% fetal calf serum. Growth medium was removed from the microwells and incubated with one of the following. The experiment was done in quadruplicates or duplicates:-

(1) 100µl of interferon α8 containing either 6, 3, 0.6, 0.3, 0.06, or 0.03 IU of interferon (Reference to Gb 23-902-531, NIH standard, distributed by the Natl. Inst. Allergy and Infectious Diseases, NIH, USA) per ml of MEM containing 2.5 mg/ml human serum albumin.

(2) 100µl of interferon α2 containing either 6, 3, 0.6, 0.3, 0.06 or 0.03 IU of interferon (Reference to Gb-23-902-530 as well as Gb-23-902-531 standards) per ml of MEM containing 2.5 mg/ml human serum albumin.

(3) 100µl of interferon β containing 60, 30, 6, 3 or 0.6 IU of interferon (Reference to Gb23-902-531 standard) per ml of MEM containing 2.5 mg/ml human serum albumin.

After the addition of interferon to the Vero cells in the microwell, 100µl of a viral challenge consisting of 100 $TCLD_{50}$ yellow fever virus, kunjin virus or dengue virus was added immediately to each of the microwells. Different concentrations of test compound were included in the viral challenge as well. In the case where no test compound was used (i.e. the viral control), only 100µl of the viral challenge was

added to the wells in 100 µl of MEM containing 2.5 mg/ml human serum albumin.

The test compounds used were cyclopentenyl cytosine (CPE-C) from the National Cancer Institute, USA; mycophenolic acid from Sigma Chemicals; 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR); and amantadine hydrochloride.

In the control cells treated with test compound alone, 100 µl of MEM containing 2.5 mg/ml human serum albumin instead of interferon was added to the cells followed by an addition of another 100 µl of MEM/human serum albumin (2.5 mg/ml) containing test compound. In the case of CPE-C, the concentrations of CPE-C in MEM were 2 µM, 0.22 µM and 0.022 µM. The subsequent concentrations of CPE-C in the wells were therefore 1 µM, 0.11 µM and 0.011 µM.

The cells were examined for virus-induced cythopathic effects on day 5, day 8 and day 9 respectively for the antiviral activities of interferon or of test compound(s) or of interferon and test compound(s) protecting against a challenge virus of yellow fever, kunjin or dengue virus. The results of the enhancement of the antiviral effect of interferon by CPE-C is given in Table 3.

Table 3

Human interferon	µM CPE-C	Fold enhancement of antiviral activity interferon
α8	1	30
α8	0.11	10
α8	0.01	0
None	1*	0
None	0.11**	0
None	0.011#	0
α2	1	10
α2	0.11	5
α2	0.01	0
None	1*	0
None	0.11**	0
None	0.011#	0

β	1	10
β	0.11	5
β	0.01	0
None	1*	0
None	0.11**	0
None	0.011#	0

* 75-90% of the Vero cells were protected against a yellow fever virus challenge of 100 $TCLD_{50}$

** 40-50% of the Vero cells were protected against a yellow fever virus challenge of 100 $TCLD_{50}$.

\# none of the Vero cells were protected against a yellow fever virus challenge of 100 $TCLD_{50}$ at this concentration of CPE-C.

Similar results in enhancement of the antiviral activity of interferon were observed when a viral challenge of 100 $TCLD_{50}$ of kunjin virus (0.11 μM of CPE-C enhanced interferon α8, interferon α2 and interferon β by 10-, 5- and 5-fold respectively) or dengue virus (0.11 μM of CPE-C enhanced interferon α8, interferon α2 and interferon β by 12-, 5- and 6-fold respectively) was used in place of yellow fever virus.

Similar experiments were repeated with mycophenolic acid, amantadine hydrochloride and EICAR. The concentration required to enhance the anti-viral activity of human interferon α8 is summarized in Table 4.

Table 4

Human interferon	μM of test compounds #	Fold enhancement of antiviral activity
α8	0.1 CPE-C(C)	10
α8	0.1 mycophenolic acid	3
α8	(MA)	3
α8	1.0 EICAR (E)	2
α8	1.0 amantadine (A)	50

# Indicates the concentration of test compound alone to protect Vero cells against a viral challenge by approximately 50%. In the case of mycophenolic acid, 2% fetal calf serum was used in place of human serum albumin.

Example 2

Monkey (Vero) or human (HuH7) cells were grown on 96 microwells as described in Example 1. When the cells were grown to 90-100% confluency with growth medium (MEM or DMEM) containing 5 or 10% fetal calf serum, the growth medium was removed from the microwells and the cells re-incubated with one of the following. The experiment was done in quadruplicates or duplicates:-

100 μl of human interferon α8, α2 or β interferon serially diluted from 30, 10, 3.3, 1.0, 0.33, 0.1, 0.033, 0.01, etc (Reference to Gb 23-902-531, NIH standard, distributed by the Natl. Inst. Allergy and Infectious Diseases, NIH, USA). In certain experiments using human cells, a serial 2-fold dilution of the interferon was used instead of the 30, 10, 3.3, 1.0, etc, dilution steps.

After adding the different concentrations of interferon to the cells in the microwells, 100 μl of a viral challenge (yellow fever, dengue, kunjin virus or VSV) was immediately added to the microwells of cells previously treated with interferon and such that the viral challenge has a final $TCLD_{50}$ of 100. Different concentrations of test compounds were added in the viral challenge. In the case where no test

compound was used (viral control) 100 µl viral challenge was added to the wells in 100 µl of MEM containing 2.5 mg/ml human serum albumin. The interferon control cells were challenged with virus without test compound. The test compound controls were challenged with virus but no interferon. The test compounds used were cyclopentenyl cytosine (CPE-C) from the National Cancer Institute, USA; mycophenolic acid from Sigma Aldrich Inc.;. 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR); amantadine hydrochloride; neplanocin A (provided by NCI, U.S.A.); 3-deazaneplanocin A (provided by NCI, USA); 3-deazauridine (Aldrich Chemical Co Inc.); NSC 382046, NSC 143095 and Artisteromycin (Sigma Aldrich Inc).

The cells were examined for virus-induced cytopathic effects on days 1, 2, 3, 4, 5, 6, 7 and 8, depending on the virus used for the antiviral activities of interferon or of test compound(s) or of interferon and test compound(s) protecting against a challenge virus of either yellow fever, dengue, kunjin virus or VSV. The results of the enhancement of the antiviral effect of the interferon used by each of the above test compounds are shown in the following Tables 5 to 22.

In the tables the IC_{50} values represent the concentration of each agent required to give a 50% inhibition of cell death following viral challenge. Where an IC_{50} value is shown as zero for one agent, that agent was not present. In those cases the IC_{50} given for the other agent is the ED_{50} of the latter alone.

CI in the tables represents the combination index. This is a parameter which reflects the presence or absence of synergism between two pharmacologically active agents. The calculation of the combination index is described by T.M. Brennan *et al* in Antiviral Research 1995, 173-187. The equation as used in the present experiments was therefore

$$CI = \left(\frac{\text{concentration of drug (b)}}{IC_{50} \text{ of drug (b) alone}} \right) + \left(\frac{\text{concentration of IFN}}{IC_{50} \text{ of IFN alone}} \right)$$

If the CI is equal to 1 the two agents have a mutually additive effect. If the CI

is less than 1 they have a synergistic effect. If the CI is greater than 1 they have a mutually antagonistic effect. (M.C. Berenbaum in Pharmacol. Rev. 41, 93-141 (1989)).

Table 5: Mycophenolic acid (MPA) and IFN in Vero cells

Virus	IFN α2 IC_{50} (IU/ml)	MPA IC_{50} (μM)	CI	IFN α8 IC_{50} (IU/ml)	MPA IC_{50} (μM)	CI	IFN β IC_{50} (IU/ml)	MPA IC_{50} (μM)	CI
Yellow fever	0.153	0	-	0.127	0	-	4.688	0	-
	0.076	0.275	0.695	0.076	0.184	0.731	1.376	1.388	0.96
	0 076	0.413	0.794	0.048	0 275	0.576	0	2.081	-
	0.048	0.619	0.757	0.048	0.413	0.675			
	0 048	0.928	0.980	0.048	0.619	0.822			
	0	1.388	-	0	1.388				
Dengue virus	0.489	0	-	0.489	0	-	4.688	0	-
	0.244	0.275	0.702	0.244	0.275	0 702	1.465	0.413	0.61
	0.153	0.413	0.610	0.076	0.413	0.453	1.465	0.619	0.758
	0.015	0.619	0.474	0.048	0.619	0.542	0.458	0.928	0.764
	0.015	0.928	0.697	0.016	0.928	0.699	0	1.388	-
	0	1.388	-	0	1.388	-			

Kunjin virus	0.092 0.014 0.009 0	0 0.413 0.619 0.928	- 0.598 0.767 -	0.092 0.009 0.009 0.009 0	0 0.275 0.413 0 619 0.928	- 0.395 0.544 0.767 -	0.916 0.286 0.090 0.286 0	0 0.413 0.619 0.928 1.388	- 0.610 0.542 0.979 -

Table 6: CPE-C and IFN in Vero cells

Virus	IFN α2 IC_{50} (IU/ml)	CPE-C IC_{50} (μM)	CI	IFN α8 IC_{50} (IU/ml)	CPE-C IC_{50} (μM)	CI	IFN β IC_{50} (IU/ml)	CPE-C IC_{50} (μM)	CI
Yellow Fever	0.489 0 153 0.048 0.048 0.024 0	0 0.017 0.025 0.038 0.056 0.085	- 0.513 0.398 0.548 0.699 -	0.489 0.153 0.153 0.048 0.048 0	0 0.017 0.025 0.038 0.056 0.085	- 0.513 0.613 0.548 0.748 -	4.688 1.465 1 465 0.458 0.045	0 0.025 0.038 0.056 0.085 0.127	- 0.513 0.613 0.531 0.676 -

Dengue virus	4.688	0	-	1 465	0	-	30	0	-
	0.229	0.142	0.144	0.458	0.017	0.345	2.930	0.285	0.231
	0.045	0.199	0.141	0.143	0.033	0.162	2.930	0.398	0.284
	0.045	0.279	0.197	0.045	0.067	0.159	0.916	0.558	0.291
	0.045	0.390	0.270	0.045	0.134	0.279	0.916	0.781	0.395
	0.045	0.547	0.374	0.045	0.268	0.535	0.286	1.093	0.519
	0.045	0.765	0.519	0	0.536	-	0.286	1.530	0.723
	0 045	1.071	0.724				0	2.142	-
	0	1.500	-						
Kunjin virus	0.293	0	-	0.293	0	-	0.916	0	-
	0.092	0.025	0.450	0.092	0.025	0.404	0 286	0.025	0.402
	0.092	0 038	0.519	0 029	0 038	0 233	0 286	0.038	0.447
	0.029	0.056	0.394	0 029	0.056	0 293	0.090	0.056	0.292
	0.009	0.085	0.485	0.029	0.085	0.397	0.045	0.085	0.348
	0.009	0.127	0.713	0.029	0.127	0.547	0.090	0127	0.546
	0	0.191	-	0.029	0.191	0.756	0	0.280	-
				0	0.286	-			

Table 7: 3-deazauridine (3-DAU) and IFN in Vero cells

Virus	IFN α2 IC_{50} (IU/ml)	3-DAU IC_{50} (μM)	CI	IFN α8 IC_{50} (IU/ml)	3-DAU IC_{50} (μM)	CI	IFN β IC_{50} (IU/ml)	3-DAU IC_{50} (μM)	CI
Yellow Fever	0.489	0	-	0.245	0		1.465	0	
	0.153	4.115	0.513	0.048	12.346	0.624	0.458	20.996	0.823
	0.077	12.346	0.757	0.015	20.576	0.776	0.143	29.394	0.812
	0	20.576	-	0	28.807		0	41.152	

Table 8: 3-deazaneplanocin A (3-DAN) and IFN in Vero cells

Virus	IFN α2 IC_{50} (IU/ml)	3-DAN IC_{50} (μM)	CI	IFN α8 IC_{50} (IU/ml)	3-DAN IC_{50} (μM)	CI	IFN β IC_{50} (IU/ml)	3-DAN IC_{50} (μM)	CI
Yellow fever	0.488	0	-	0.488	0	-	1.465	0	-
	0.015	0.725	0.395	0.076	0 725	0.416	0.143	0.725	0.462
	0.015	1.015	0.541	0.048	1.015	0.463	0.143	1.015	0.608
	0.015	1.420	0.745	0.015	1.420	0.541	0.143	1 420	0.812
	0	1.989	-	0	1.989	-	0	1 989	-
Dengue virus	1.465	0	-	1.465	0	-	9.375	0	-
	0.458	0.725	0.677	0.143	0.725	0.462	0.915	1.015	0.608
	0.143	1.015	0.608	0.045	1 015	0.541	0 089	1.420	0.724
	0.045	1.420	0.745	0.045	1.420	0.745	0	1.989	-
	0	1.989	-	0	1 989	-			

Table 9: 6-azauridine (6-AU) and IFN in Vero cells

Virus	IFN α2 IC_{50} (IU/ml)	6-AU IC_{50} (μM)	CI	IFN α8 IC_{50} (IU/ml)	6-AU IC_{50} (μM)	CI	IFN β IC_{50} (IU/ml)	6-AU IC_{50} (μM)	CI
Yellow fever	0.153	0	-	0.321	0	-	2.271	0	-
	0.048	1.224	0.811	0.153	0.816	0.762	1.465	0.816	0.931
	0.015	1.633	0.765	0.048	1.224	0.578	0.458	1.224	0 630
	0.015	2.041	0.932	0.048	1.633	0.721	0.458	1.633	0.773
	0	2.449	-	0.015	2.041	0.761	0.143	2.041	0.777
				0.048	2.449	1.007	0.458	2.449	1.059
				0	2.857	-	0	2.857	-

Table 10: NSC 382046 and IFN in Vero cells against Dengue virus

IFN α 2 IC_{50} (IU/ml)	NSC 382046 IC_{50} (μM)	CI
4.688	0	-
1.465	0.095	0.758
0.045	0.141	0.672
0	0.212	-

Table 11: NSC 7364 and IFN in Vero cells against Dengue virus

IFN α 2 IC_{50} (IU/ml)	NSC 7364 IC_{50} (μM)	CI	IFN α 8 IC_{50} (IU/ml)	NSC 7364 IC_{50} (μM)	CI
1 465	0	-	4.688	0	-
0.733	0.186	0.834	1.465	0.372	0.813
0 458	0.372	0.979	0	0.743	-
0	0.558	-			

Table 12: NSC 143095 and IFN in Vero cells against yellow fever virus

IFN α 2 IC_{50} (IU/ml)	NSC 143095 IC_{50} (μM)	CI	IFN α 8 IC_{50} (IU/ml)	NSC 143095 IC_{50} (μM)	CI
0.458	0	-	0.153	0	-
0.143	0.848	0.756	0.048	0.386	0.813
0.045	1.272	0.763	0	0.772	-
0	1.907	-			

IFN β IC_{50} (IU/ml)	NSC 143095 IC_{50} (μM)	CI
2.930	0	-
0.287	1.272	0.764
0	1.907	-

Table 13: Mycophenolic acid (MPA) and IFN α8 in human cells against VSV and yellow fever virus

Virus	Cell type	IFN α 8 IC_{50} (IU/ml)	MPA IC_{50} (μM)	CI
VSV	MRC 5	0	4.1	-
		4.9	0	-
		0.02	3.9	0.96
		0.01	2.6	0.64
		0.01	1.7	0.43
		0.21	1.2	0.33
		0.43	0 8	0.28
		1.22	0.5	0.37
		2.18	0.3	0.53
		4.39	0.2	0.95
		4.65	0.2	0.98
	HuH7	0	1.72	-
		2.06	0	-
		0.13	0.72	0.48
		0.38	0.48	0.46
		0.77	0.32	0.56

Yellow fever	HuH7	0	3.86	-
		7.85	0	-
		1.73	2.48	0.86
		1.94	1.65	0.68
		1.94	1.10	0.53
		1.22	0.73	0.35
		2.76	0.49	0.48
		6.99	0.33	0.97

Table 14: CPE-C and IFN in human cells against VSV and kunjin virus.

Cell type	Virus	IFN β IC_{50} (IU/ml)	CPE-C IC_{50} (μM)	CI
HuH7	VSV	0	4.18	-
		35.7	0	-
		0.81	1.84	0.46
		0.81	1.23	0.32
		0.81	0.82	0.22
		1.08	0.55	0.16
		1.94	0.36	0.14
		2.59	0.24	0.13
	Kunjin	0	0.37	-
		2.59	0	-
		0.20	0.25	0.75
		0.23	0.17	0.54
		0.08	0.11	0.33
		0.81	0.07	0.51
		1.83	0.01	0.84

Cell type	Virus	IFN α 8 IC_{50} (IU/ml)	CPE-C IC_{50} (μM)	CI
MRC-5	VSV	0	2.26	-
		3.10	0	-
		0.19	2.09	0.98
		0.61	1.39	0.81
		1.22	0.93	0.80
		2.45	0.41	0.97
		1.94	0.28	0.75
		2.18	0.18	0.79
		2.18	0.12	0.76
		2.18	0.08	0.74

Table 15: 3-deazaneplanocin A (3-DAN) and IFN in human cells against VSV

Cell type	3-DAN	IFN IC_{50} (IU/ml)		CI
		IFN α8	IFN β	
MRC 5	0.172	0		-
	0	3.10		-
	0.115	0.38		0.79
	0.076	1.09		0.80
	0.051	1.94		0.92
	0.034	2 18		0.90
	0.023	2.18		0.84
	0.015	2.45		0.88
	0.010	2 45		0.85

HuH7	0.126		0	-
	0		19.80	-
	0.095		0.54	0.79
	0.064		0.54	0.54
	0.042		0.86	0.38
	0.028		1.22	0.29
	0.019		1.94	0.25
	0.013		2.18	0.21

Table 16: 6-azauridine (6-AU) and IFNβ in human cells against VSV

Cell type	IFN β IC_{50} (IU/ml)	6-AU IC_{50} (μM)	CI
MRC 5	0	80.8	-
	2.20	0	-
	0.38	25.3	0.49
	1.09	7.8	0.59
	1.22	2.4	0.59

Table 17:NSC 382046 and IFNβ in human HuH7 cells against yellow fever and kunjin virus

Virus	IFN β IC_{50} (IU/ml)	NSC 382046 IC_{50} (μM)	CI
Yellow fever	0	0.350	-
	2.59	0	-
	0.81	0.192	0.86
	0.72	0.128	0.64
	0.57	0.085	0.46
	0.57	0.057	0.38
	0.57	0.038	0.33
	0.72	0.025	0.35
	0.81	0.017	0.36
	0.81	0.011	0.34
Kunjin virus	0	5.264	-
	18.74	0	-
	8.30	2.865	0.99
	11.10	1.910	0.96
	11.10	1.273	0.83
	11.10	0.849	0.75
	11.10	0.566	0.70

Table 18: NSC 143095 and IFNβ in human HuH7 cells against yellow fever virus and VSV.

Virus	IFN β IC_{50} (IU/ml)	NSC 143095 IC_{50} (μM)	CI
VSV	0	11.822	-
	6.21	0.00	-
	0.08	6.448	0.56
	0.08	4.299	0.38
	0.25	2.866	0.28
	0.57	1 910	0.25
	1.83	1.274	0.40
	3.68	0.849	0.66
Yellow fever	0	0.510	-
	2.06	0 00	-
	0.08	0.340	0.71
	0.25	0.227	0.57
	0.81	0.151	0.69

Table 19: Tiazofurin and IFNβ in human HuH7 cells against yellow fever virus and kunjin virus

Virus	IFNβ IC_{50} (IU/ml)	Tiazofurin IC_{50} (μM)	CI
Yellow fever	0	7.538	-
	0.37	0	-
	0.01	6.154	0.85
	0.05	4.103	0.68
	0.10	1.823	0.51
	0.28	0.812	0 87
Kunjin virus	0	6.923	-
	0.20	0	-
	0.01	4.615	0.73
	0.01	3.077	0.51
	0.02	2.051	0.38
	0.03	1.368	0.32
	0.04	0.912	0.33
	0.04	0.608	0.29
	0.08	0.405	0.46

Table 20: Selenofurin and IFNβ in human HuH7 cells against yellow fever virus and kunjin virus

Virus	IFNβ IC_{50} (IU/ml)	Selenofurin IC_{50} (μM)	CI
Yellow fever	0	0.472	-
	0.43	0	-
	0.05	0.391	0.94
	0.04	0.261	0.65
	0.07	0.173	0.53
	0.16	0 117	0.62
	0.16	0.052	0.49
Kunjun virus	0	0.717	-
	0.20	0	-
	0 01	0 554	0.84
	0.01	0.369	0.58
	0.05	0.164	0.48
	0.05	0.109	0.40
	0.08	0.073	0.51
	0.08	0.049	0.47

Table 21: Amantadine and human IFN in human cells against VSV and kunjin virus

Cell Type	Virus	Amantadine IC_{50} (μM)	IFN IC_{50} (IU/ml)		CI
			IFN α8	IFN β	
MRC-5	VSV	913.8	0		-
		0	0.81		-
		584.9	0.12		0.79
		390.1	0.27		0.76
		259.9	0.27		0.62
		173.0	0.38		0.66
		115.8	0.61		0.87
HuH7	Kunjin virus	115.7		0	
		0		0.13	
		77		0.01	0.76
		51.3		0.04	0.76

Table 22: Neplanocin A and human IFN in human cells against VSV and Yellow Fever Virus

Cell Type	Virus	Neplanocin A IC_{50} (μM)	IFN IC_{50} (IU/ml)		CI
			IFN α8	IFN β	
MRC-5	VSV	2.9	0		-
		0	2.18		-
		2.2	0.04		0.80
		1.5	0.09		0.56
		1.0	0.12		0.40
		0.7	0.97		0.67
		0.4	1.22		0.71

HuH7	Yellow	9.3		0	
	Fever	0		5.86	
		5.1		0.01	0.63
		3.4		0.04	0.71
		2.2		2.06	0.59

Example 3

By following the experimental procedure described in Examples 1 and 2 the compound NSC 184692 was found to have an ED_{50} against dengue virus of 120 pM in monkey Vero cells subjected to viral challenge by 100 $TCLD_{50}$ dengue virus. It was found that 100 pM of the compound enhanced the anti-viral effect of human IFNβ 10-fold.

CLAIMS

1. Use, in the manufacture of a medicament for the treatment of a flavivirus or rhabdovirus infection, of:

(a) an interferon, and

(b) at least one compound selected from the group consisting of:

- 5-membered cyclic nucleosides having the formula (I):



(I)

wherein ⌢ X ⌢ is =CH-, $-CH_2-$ or -O-, Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;

- mycophenolic acid compounds having the formula (II)



(II).

wherein R_4 is $-OR_6$ or $-N(R_7)\,R_8$ in which R_6, R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1-C_6 alkyl, and R_5 is selected from the group consisting of hydrogen, phenyl and C_1-C_6 alkyl unsubstituted or substituted by a five- or six-membered saturated or

unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;

- imidazole derivatives represented by formula (III):



(III).

wherein R_9 is a hydrogen atom or



wherein R_{10} is a hydrogen atom, C_1-C_6 alkyl, hydroxy(C_1-C_6 alkyl) or phenyl, R_{11} and R_{13} are independently selected from hydrogen and OR_{12} and R_{12} is a hydrogen atom or a hydroxy protecting group and A is $CONH_2$ or CN, and pharmaceutically acceptable salts thereof;

- aminoadamantanes having the formula (IV):



(IV).

wherein each of R_{14}, R_{15}, R_{16} and R_{17} is independently selected from the group consisting of H, F and CH_3 and X is $N(R_{18})_2$, $CH_2CH_2N(R_{18})_2$ or $C(R_{19})_2N(R_{18})_2$ wherein each R_{18} and R_{19} is H, (C_1-C_6) alkyl, (C_6-C_{10}) aryl and (C_7-C_{18}) aralkyl; and

- 2,4-diaminopyrimidines having the formula (V):



(V)

wherein R_{20} is phenyl substituted by one or more substituents selected from the group consisting of benzyl, NO_2, (C_1-C_6) alkylamino and halogen and R_{21} is H or C_1-C_6 alkyl; or R_{20} and R_{21} form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):



(V')

wherein Z is $-CH_2NR_{23}-$ or $-NR_{23}CH_2-$; R_{22}, R_{23} and R_{24} are each, independently, H or C_1-C_6 alkyl; and n is 1 or 2,and pharmaceutically acceptable salts thereof.

2. Use of an interferon in the manufacture of a medicament for use with at least one compound (b) as defined in claim1 in the treatment of a flavivirus or rhabdovirus infection.

3. Use of at least one compound (b) as defined in claim 1 in the manufacture of a medicament for use with an interferon in the treatment of a flavivirus or rhabdovirus infection.

4. Use according to any one of claims 1 to 3, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

5. Use according to any one of claims 1 to 3 wherein the rhabdovirus is selected from vesicular stomatitis virus (VSV) and rabies virus.

6. Use according to any one of claims 1 to 3 wherein the interferon (a) is a human interferon.

7. Use according to any one of claims 1 to 3 wherein the interferon is selected from interferon α2, interferon α8 and interferon β.

8. Use according to claim 7, wherein the interferon is human interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg protein.

9. Use according to claim 7, wherein the interferon is human interferon β having a specific activity of from $4x10^8$ to $8x10^8$ per mg protein.

10. Use according to any one of the preceding claims wherein the compound (b) is at least one compound selected from cyclopentenyl cytosine, mycophenolic acid, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide, amantadine hydrochloride, 3-deazaneplanocin, neplanocin A, 3-deazauridine, 6-azauridine, aristeromycin, pyrazofurin, tiazafurin, selenofurin, NSC 382046, NSC 7364, NSC 302325, NSC 184692D and NSC 382034.

11. Products containing an interferon and at least one compound (b) as defined in claim 1 as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection.

12. Use, in the manufacture of a medicament for the treatment of a flavivirus or rhabdovirus infection, of an interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg protein.

13. Use according to claim 12, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

14. Use according to claim 12, wherein the rhabdovirus is VSV.

15. Use according to claim 12, wherein the interferon α8 is human interferon α8.

16. Interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg of protein for use in a method of treatment of the human or animal body by therapy.

17. Interferon α8 according to claim 16 for use in the treatment of a

flavivirus or rhabdovirus infection.

18. Use of interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg of protein in the manufacture of a medicament for use in the treatment of a flavivirus or rhabdovirus infection.

19. An anti-flavivirus or anti-rhabdovirus agent comprising interferon α8 having a specific activity of from $0.6x10^9$ to $1.5x10^9$ IU per mg of protein.

20. A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic antiflaviviral or antirhabdoviral effect, an interferon and at least one compound (b) as defined in claim 1.

21. An agent for use in the treatment of a flavivirus or rhabdovirus infection, which comprises an interferon and at least one compound (b) as defined in claim 1.

N.76187D

Attorney's Docket No. 117-363

09/914184

RULE 63 (37 C.F.R. § 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As below named inventor(s), I/we hereby declare that

This declaration is of the following type:

☐ original	☐ design	☐ supplemental
☒ national stage of PCT		
☐ divisional	☐ continuation	☐ continuation-in-part

My/our residence, post office address and citizenship are as stated below next to my/our name.

I/we believe I/we am/are the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR TREATMENT OF VIRAL-MEDIATED DISEASES

the specification of which (check one)

☐ is attached hereto

☐ was filed on _____
in the United States Patent and Trademark Office as Application Serial No. _____
and was amended on _____ *(if applicable)*

☐ was described and claimed in PCT International Application No. **PCT/US00/04699**
filed on **25 Feb 2000**
and as amended under PCT Article 19 on _____ *(if any)*

I/we hereby state that I/we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I/we acknowledge the duty to disclose information which is material to patent ability as defined in 37 C.F.R. § 1.56.

I/we hereby claim foreign priority benefits under 35 U.S.C §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or under § 365(a) of any PCT International Application(s) which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International Application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119

Application No.	Country	Filing Date	Priority Claimed	
			Yes	No
60/121,931	US	26 Feb 1999	X	
60/181,068	US	8 Feb 2000	X	
PCT/US00/04699		25 Feb 2000		

I/we hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below:

UNITED STATES PROVISIONAL APPLICATION(S)

Application No.	Filing Date

I/we hereby claim the benefit under 35 U.S.C. § 120 of any United States Application(s) or § 365(c) of any PCT International Application(s) designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I/we acknowledge the duty to disclose information which is material to patent ability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior applicat ion and the national PCT international filing date of this application.

PRIOR UNITED STATES/PCT INTERNATIONAL APPLICATION(S)

Application No.	Filing Date	Status (patented, pending/abandoned)
PCT/US00/04699	25 Feb 2000	

And I hereby appoint **Nixon & Vanderhye P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201-4714, telephone number (703) 816-400 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205.

I/we hereby declare that all statements made herein of my/our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C § 1001 and that such willful false statements may jeopardise the validity of the application or any patent issued thereon.

COMBINED DECLARATION AND POWER OF ATTORNEY

		24 September 2001
Inventors Signature		Date
Full name of first/sole inventor	Yin Hwee TAN	
Citzenship	Singapore	
Residence(City)	Singapore	SGX
Post Office Address	30 Medical Drive Singapore 117609 Singapore	

		27 SEPTEMBER 2001
Inventors Signature		Date
Full name of 2nd inventor	John Stanford DRISCOLL	
Citzenship	United States of America	
Residence(City)	United States of America	
Post Office Address	of 4 Infield Court South Rockville Maryland 20854 United States of America	MD